Cereno Scientific has received approval to initiate a sub-study within its Expanded Access Program (EAP) for CS1, a drug candidate aimed at treating pulmonary arterial hypertension. The study will use Functional Respiratory Imaging (FRI) technology, developed by Fluidda, to monitor changes in small pulmonary arteries over a 12-month period.
This innovative approach aims to explore CS1’s potential to reverse pathological vascular remodeling, a key factor in pulmonary arterial hypertension progression. The findings will support future clinical trials and regulatory decisions, offering hope for improved long-term outcomes in patients.
For more information about the study, you can visit this link
See also our previous article on CS1 here